Mirum Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
August 10 2022 - 11:59PM
Business Wire
Mirum Pharmaceuticals, Inc. (Nasdaq: MIRM) today announced that
on August 10, 2022, the Compensation Committee of Mirum’s Board of
Directors granted inducement awards consisting of non-qualified
stock options to purchase 28,250 shares of common stock and 14,100
restricted stock units (“RSUs”) to eight new employees under
Mirum’s 2020 Inducement Plan. The Compensation Committee of Mirum’s
Board of Directors approved the awards as an inducement material to
the new employees’ employment in accordance with Nasdaq Listing
Rule 5635(c)(4).
Each stock option has an exercise price per share equal to
$24.93 per share, Mirum’s closing trading price on August 10, 2022,
and will vest over four years, with 25% of the underlying shares
vesting on the one-year anniversary of the applicable vesting
commencement date and the balance of the underlying shares vesting
monthly thereafter over 36 months, subject to the new employees’
continued service relationship with Mirum through the applicable
vesting dates. The RSUs will vest over three years, with 33% of the
underlying shares vesting on each anniversary of the applicable
vesting commencement date, subject to the new employees’ continued
service relationship with Mirum through the applicable vesting
dates. The awards are subject to the terms and conditions of
Mirum’s 2020 Inducement Plan and the terms and conditions of an
applicable award agreement covering the grant.
About Mirum Pharmaceuticals, Inc. Mirum Pharmaceuticals,
Inc. is a biopharmaceutical company dedicated to transforming the
treatment of rare diseases. Mirum’s approved medication is
LIVMARLI® (maralixibat) oral solution which is approved in the U.S.
for the treatment of cholestatic pruritus in patients with Alagille
syndrome one year of age and older. Please view the warnings and
precautions available in the Prescribing information or, for more
information, visit LIVMARLI.com.
Mirum’s late-stage pipeline includes two investigational
treatments for debilitating liver diseases affecting children and
adults. Maralixibat (LIVMARLI), an oral ileal bile acid transporter
(IBAT) inhibitor, is currently being evaluated in clinical trials
for pediatric liver diseases and includes the MARCH Phase 3 study
for progressive familial intrahepatic cholestasis (PFIC) and the
EMBARK Phase 2b study for patients with biliary atresia. In
addition, Mirum has an expanded access program open across multiple
countries for eligible patients with ALGS and PFIC.
Mirum has submitted a Marketing Authorization Application to the
European Medicines Agency for maralixibat for the treatment of
cholestatic liver disease in patients with Alagille syndrome.
Mirum’s second investigational treatment, volixibat, an oral
IBAT inhibitor, is being evaluated in three potentially
registrational studies including the VISTAS Phase 2b clinical trial
for adults with primary sclerosing cholangitis, the OHANA Phase 2b
clinical trial for pregnant women with intrahepatic cholestasis of
pregnancy, and the VANTAGE Phase 2b clinical trial for adults with
primary biliary cholangitis.
Learn more about Mirum by visiting www.mirumpharma.com. Follow
Mirum on Twitter, Facebook, LinkedIn and Instagram.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20220810005857/en/
Investor Contacts: Ian Clements, Ph.D. ir@mirumpharma.com
Sam Martin Argot Partners ir@mirumpharma.com Media Contact:
Erin Murphy media@mirumpharma.com
Mirum Pharmaceuticals (NASDAQ:MIRM)
Historical Stock Chart
From Mar 2024 to Apr 2024
Mirum Pharmaceuticals (NASDAQ:MIRM)
Historical Stock Chart
From Apr 2023 to Apr 2024